Cedar Associates LLC conducts statistical and econometric analyses of retrospective databases, clinical trial data, and administrative claims data. Our staff has experience programming in SAS, STATA, S-Plus, Mathematica, and R-statistical language. Our analyses have been published in peer-reviewed journals, submitted to FDA, and submitted to reimbursement agencies (CMS, UK NICE). Having worked on more than 100 clinical trials, we have experience with survival models, ANOVA models, multivariate regression (Cox, GLM, GEE, fixed and random effect models, logistic), time series, and Bayesian methods and forecasting. We also emphasize clarity in our preparation using state-of-the-art graphics and presentation styles. We also have extensive experience in data cleaning and management.

Recent Projects

Relationship between Antiretroviral Prescribing Patterns and Treatment Guidelines in Treatment-Naïve, HIV-1 Infected U.S. Veterans: 1992-2004

We evaluated ARV prescribing patterns among ARV treatment-naïve veterans who were receiving care within the U.S. Department of Veterans Affairs (VA) from 1992 thru 2004 in comparison to evolving adult HIV-1 treatment guidelines.  ARV data were analyzed using the US Department of Veterans Affairs immunological case registry (ICR), which contains demographic and clinical data from VA clinical records. The results of this project are to published soon in JAIDS.

Forecasting Visual Acuity in Patients with Clinical Significant Macular Edema.  

Cedar undertook a secondary analysis of the largest randomized controlled trial of eye diseases, the Early Treatment of Diabetic Retinopathy Study (ETDRS), provided to us by the National Eye Institute of the NIH. We assessed using multivariate regression and time-series models the predictors of worsening visual acuity among patients with clinical significant macular edema. This study is intended to inform FDA deliberations concerning optimal endpoints of randomized trials for this condition.

Safety and Efficacy of Treatments of Diabetic Macular Edema

Cedar was asked to reanalyze the results of a randomized controlled trial, the results of which have been published, to assist FDA in better understanding implications of different clinical endpoints of randomized trials for this condition. Our analyses involved using extensive exploratory graphical methods and analyses of trends to reveal the most reliable and credible markers of disease progression.

Forecasting Numbers of Enrollees and Costs of HRSA’s AIDS Drug Assistance Program (ADAP)

Dr. Hornberger was the Principal Investigator of a project to assess trends in the number of enrollees and costs of the Health Resources and Services Administration’s ADAP.  He used time-series analyses to derive these forecasted estimates. The findings were used by HRSA and other government agencies to inform the recent reauthorization of the Ryan White Care Act.